Table 3.
Patients with late recurrence after initial treatment
| Stage | Histology | Initial treatment added to radical orchiectomy | Time to relapse (months) | Site of relapse | Tumor markers at relapse (AFP/HCG-β) | Outcome | Period after the treatment for recurrent disease (months) |
|---|---|---|---|---|---|---|---|
| I | E + T + S | None | 26 | RPLN, lung | 24.9/1.5 | NED | 65 |
| I | S | None | 46 | Dura mater | 1.2/0.1 | NED | 105 |
| I | T + S | None | 84 | RPLN | 465/0.2 | NED | 5 |
| I | E + T | RPLND | 25 | RPLN | 69.0/5.0 | NED | 196 |
| IIIB2 | E + Y + C + T | Chemotherapy + tumor resection | 59 | Mediastinum | 1085/69.0 | NED | 115 |
AFP, α-fetoprotein; HCG-β, human chorionic gonadotropin-β subunit; E, embryonal carcinoma; T, teratoma; S, seminoma; RPLN, retroperitoneal lymph nodes; NED, no evidence of disease; Y, yolk sac tumor; C, choriocarcinoma. HCG was not examined at the time of relapse in these cases.